2211-57-6

Basic information

• Product Name: N'-BENZYLGUANIDINEACETATE
• Synonyms: N'-BENZYLGUANIDINEACETATE;benzylguanidine;N-Phenethyl-guanidine hemisulfate salt;1-Benzylguanidine;N-Benzylguanidinium acetate;N-benzylguanidine(SALTDATA: 0.92CH3COOH 0.4H2O);2-Benzylguanidine acetate;N-Benzyl Guanidine Hydrochloride
• CAS NO: 2211-57-6
• Molecular Formula: C₈H₁₁N₃
• Molecular Weight: 149.19
• Product Categories: Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 2211-57-6.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 300°C at 760 mmHg
• Flash Point: 135.2°C
• Appearance: /
• Vapor Pressure: 0.00115mmHg at 25°C
• CAS DataBase Reference: N'-BENZYLGUANIDINEACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: N'-BENZYLGUANIDINEACETATE(2211-57-6)
• EPA Substance Registry System: N'-BENZYLGUANIDINEACETATE(2211-57-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 2211-57-6(Hazardous Substances Data)

Usage

General Description

N'-benzylguanidineacetate is a chemical compound that is derived from guanidine and has a benzyl group attached to the nitrogen atom. It is commonly used as a reagent in organic synthesis for the synthesis of various compounds. N'-BENZYLGUANIDINEACETATE has potential applications in medicinal chemistry as it has been studied for its antitumor and antiviral properties. N'-benzylguanidineacetate has also been investigated for its potential use as a chelating agent and as a catalyst in organic reactions. Its unique chemical structure makes it a versatile and valuable compound in various fields of research and development.

InChI:InChI=1/C8H11N3.H2O4S/c9-8(10)11-6-7-4-2-1-3-5-7;1-5(2,3)4/h1-5H,6H2,(H4,9,10,11);(H2,1,2,3,4)

Upstream product

• 6630-99-5 1,2,3,4-thiatriazole-5-amine 
• 674-81-7 nitrosoguanidine 
• 100-46-9 benzylamine 
• 1415910-64-3 C₈H₁₁N₃*H₂O₃S 
• 1000875-21-7 N,N''-bis(tert-butoxycarbonyl)-N-(3-trimethylstannylbenzyl)guanidine 
• 4023-02-3 1H-pyrazole-1-carboximidamide hydrochloride 
• 14527-26-5 2-methylisothiourea sulphate 
• 19503-22-1 1H-benzotriazole-1-carboxamidine hydrochloride 
• 145013-06-5 N,N′-bis(tert-butoxycarbonyl)-N′′-benzylguanidine 
• 7732-18-5 water 
• 17356-08-0 thiourea 
• 145013-06-5 C₁₈H₂₇N₃O₄ 
• 29427-58-5 O-methylisourea hemisulfate 
• 38184-47-3 3,5-dimethyl-1-pyrazolylformaminidium nitrate 

Downstream Products

• 1197002-83-7 1,2-diacetyl-3-benzylguanidine 
• 88637-00-7 2-benzylamino-6-methylpyrimidin-4(3H)-one 
• 106270-42-2 N-benzyl-2-amino-4,6-dimethylpyrimidine 
• 89242-69-3 N²-benzyl-4-methyl-6-phenyl-2-pyrimidineamine 
• 2898-76-2 benzamil 
• 1383716-48-0 N₂'-benzyl-4'-(cyclopropylmethyl)-N₂-(pyridin-4-yl)-[4,5'-bipyrimidine]-2,2'-diamine 
• 1421333-37-0 N¹-benzyl-N²,N³-diisopropylguanidine 
• 1435840-49-5 N¹,N²,N⁶,N⁷-tetraisopropyl-N⁴-benzyltriguanide acetate 
• 1435840-98-4 4-benzylamino-1-isopropyl-6-isopropylamino-2-isopropylimino-1,2-dihydro-1,3,5-triazine acetate 
• 78822-77-2 N¹-cyano-N²,N³-diisopropylguanidine 
• 81547-11-7 Benzyl-(1-oxy-1,2,4,9-tetraaza-phenanthren-3-yl)-amine 

Relevant articles and documents

Large-scale synthesis of no-carrier-added [123I]mIBG, using two different stannylated precursors

The clinical advantages of no-carrier-added (n.c.a) radioiodinated meta-iodobenzylguanidine ([*I]mIBG) over its carrieradded (c.a.) analogue have previously been reported. A large-scale synthesis of n.c.a. [ 123I]mIBG was therefore investigated

Production of new amilorides as potent inhibitors of mitochondrial respiratory complex I

Amilorides, well-known inhibitors of Na+/H+ antiporters, have also shown to inhibit bacterial and mitochondrial NADH-quinone oxidoreductase (complex I). Since the membrane subunits ND2, ND4, and ND5 of bovine mitochondrial complex I

CURABLE COMPOSITION

The present invention has its object to provide a curable composition which comprises a guanidine compound as a non-organotin type catalyst, is less discolored, has good surface curability, depth curability, strength rise and adhesiveness, and can retain the curability even after storage; the above object can be achieved by a curable composition which comprises: (A) an organic polymer containing a silyl group capable of crosslinking under siloxane bond formation, the silyl group being a group represented by the general formula (1): -SiX 3 (1) (wherein X represents a hydroxyl group or a hydrolyzable group and the three X groups may be mutually the same or different), (B) a guanidine compound (B-1) as a silanol condensation catalyst, and (C) a plasticizer, wherein the content of the component (B-1) is not lower than 0.1 part by weight but lower than 8 parts by weight per 100 parts by weight of the component (A), and a non-phthalate ester plasticizer accounts for 80 to 100% by weight of the (C) component plasticizer.